However, the increase in CD11c+/CD206− ratio in NASH group was suppressed by sh-Lp-PLA2, rapamycin, and/or JAK2-inhibitor treatment (P < 0.01). Here, JAK2 is linked to metabolic dysfunction-associated steatohepatitis.